• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Outcomes favorable in 2-year experience with silicone IOL

Article

San Diego - Two-year follow-up of eyes with the ClariFlex with OptiEdge silicone IOL (AMO) implanted show that the second-generation silicone IOL with its novel edge design is performing well. Furthermore, risk of posterior capsular opacification (PCO) and glare was minimal, according to the results of a study presented by Elizabeth A. Davis, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.